A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)	Genital Diseases, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, male reproductive organ cancer, male reproductive system disorder, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, primitive neuroectodermal tumor, prostate cancer, prostate disorder, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma	Active, not recruiting	Phase 1 / Phase 2	2026-02-24		NCT04471727

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Daiichi Sankyo	144
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	2

11 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Cedar-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute	Los Angeles	United States	1
Dana Farber Cancer Institute	Boston	United States	1
Karmanos Cancer Center	Detroit	United States	16
Medical College of Wisconsin	Milwaukee	United States	483
Memorial Sloan Kettering Cancer Center	New York	United States	60
Providence	Portland	United States	2
Roswell Park Comprehensive Cancer Center	Buffalo	United States	63
Tennessee Oncology	Nashville	United States	77
University Hospitals Cleveland Medical Center	Cleveland	United States	234
University of California San Francisco	San Francisco	United States	144
University of Colorado	Aurora	United States	147